The respiratory system is the defining element for all active living beings who breathe air. Recently the covid-19 pandemic has consumed the global human population through respiratory disease, leaving a trail of loss and devastation. Respiratory Conference 2023 invites you to join the “4th International Conference on Respiratory Disease and Care” in Zurich, Switzerland. This Respiratory Conference comes at a very critical time to review what we have learned thus far and what we can propose going forward to protect and prevent situations like SARS-CoV-2 and many others. With this aim, this Respiratory Conference will attract all levels of pulmonologists, researchers, and industry personnel to a common platform for crucial collaborations to secure effective healthcare services for the future. The goal of Longdom Conferences is to bring together scientists at every level from diverse disciplines to understand and discuss throughout the programmed sessions and comfortable gatherings. All these opportunities will support the professional growth of younger scientists that will promote future collaborations and enhance participation and contribution to their exciting research work.

Market Analysis Report on Chronic Obstructive Pulmonary Disease:

Global chronic obstructive pulmonary disease treatment market revenue was worth USD 16,784 million in 2021, with a 4.9% CAGR from 2022 to 2030. North America region was accounted 41% of chronic obstructive pulmonary disease treatment market share in 2021. Asia-Pacific COPD treatment market growth is expected to enlarge at a CAGR of 6% from 2022 to 2030. By distribution channel, hospital pharmacies sector capture over 51% of the overall market share in 2021. Growth in the prevalence of COPD among peoples, drives the chronic obstructive pulmonary disease treatment market value.

Chronic Obstructive Pulmonary Disease Treatment Market Overview

Chronic obstructive pulmonary disease (COPD) comprises chronic bronchitis, wherein the bronchi (large air channels) become inflamed & scarred, as well as emphysema, in which the alveoli get destroyed. The consequences of COPD can range from mild to severe. COPD is treated with a combination of non-pharmacological & pharmacological therapies. Risk reduction (smoking cessation) and avoiding and treating co-morbidities are examples of non-pharmacological therapies which are cardiovascular disease, depression, anxiety, and others.

Chronic Obstructive Pulmonary Disease Treatment Market Trends

In recent years, various market participants have received approval from the Food and Drug Administration (FDA), the European Commission, as well as other administrative specialists. These players have introduced new items into the market, such as triple therapy medications and various blends, allowing them to enhance their significant market share of the whole sector. AstraZeneca received European Commission (EC) approval in December 2018 for Bevespi Aerosphere in a pressurized metered-portion inhaler (pMDI) shown as an ongoing double bronchodilator treatment in grown-up patients with COPD. This approval allowed the firm to add its innovatively developed item to the current product offering for patients in Europe. Moreover, Teva Pharmaceutical Industries Ltd. received FDA approval for ProAir Digihaler inhaler powder in December 2018, which is a digital inhaler with intrinsic sensors designed for a sidekick diverse application. This affirmation aided the organization in fortifying its development abilities in respiratory consideration, resulting in driving the chronic obstructive pulmonary disease treatment market growth.

Visit for more information and join us: https://www.longdom.com/respiratoryconference/sponsors

Relevant Conferences:

Respiratory Conferences | Respiratory Meetings | Respiratory Workshops | Pulmonology Meetings | Pulmonology Symposiums | Pulmonology Workshops | Pulmonology Conferences | Lung Transplant Conferences |  Lung Transplant workshops | Lung Transplant Meetings | Pulmonary Vascular Diseases Conferences